Clinical trial · Interventional
Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer
Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate the effectiveness of alpha-lipoic acid (ALA) for improving I-131 uptake in recurrent or metastatic of DTC with defective I-131 uptake.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Thyroid | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| alpha-lipoic acids | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Low dose group
- description
- Patients who will receive 600 mg/day alpha-lipoic acid
- interventionNames
- Drug: alpha-lipoic acids
- type
- ACTIVE_COMPARATOR
- label
- High dose group
- description
- Patients who will receive 1,200 mg/day alpha-lipoic acid
- interventionNames
- Drug: alpha-lipoic acids
Primary outcomes (1)
- measure
- Increment of radioactive iodine uptake
- timeFrame
- 3months after alpha-lipoic acid treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. aged 20 to 75 years 2. under birth control, if fertile women 3. Groups * who received radioactive iodine treatment for recurrent and metastatic thyroid cancer, and did not showed any uptake at post-therapeutic whole body scan * who planned to receive empirical radioactive treatment due to high expected recurrence Exclusion Criteria: * allergic to alpha-lipoic acid * severe heart failure, lung disease, or end-stage renal disease * liver function abnormalities (x2.5 above normal limits) * neuropsychologically unstable patients * previous history of drug medication such as oral steroid, digoxin, theophylline, carbamazepine, valproic acid, phenobarbital, methotrexate, cyclosporin, tacrolimus within 3 months before this recruitment. * who is already taking alpha-lipoic acid for other purpose.
References
Publications (0)
Data not yet available